Adil E Bharucha1, Barbara Batey-Schaefer2, Patricia A Cleary3, Joseph A Murray4, Catherine Cowie5, Gayle Lorenzi6, Marsha Driscoll7, Judy Harth7, Mary Larkin8, Marielle Christofi8, Margaret Bayless9, Nyra Wimmergren10, William Herman11, Fred Whitehouse12, Kim Jones12, Davida Kruger12, Cathy Martin11, Georgia Ziegler13, Alan R Zinsmeister14, David M Nathan8. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: bharucha.adil@mayo.edu. 2. Division of Endocrinology, Northwestern University, Chicago, Illinois. 3. Biostatistics Center, George Washington University, Washington, District of Columbia. 4. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 5. Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Washington, District of Columbia. 6. Division of Endocrinology, University of California-San Diego, San Diego, California. 7. Division of Endocrinology, University of Western Ontario, London, Ontario, Canada. 8. Diabetes Research Center, Massachusetts General Hospital, Boston, Massachusetts. 9. Division of Endocrinology, University of Iowa General Hospital, Iowa City, Iowa. 10. Division of Endocrinology, University of Minnesota, Minneapolis, Minnesota. 11. Division of Endocrinology, University of Michigan, Ann Arbor, Michigan. 12. Department of Endocrinology, Henry Ford Medical-New Center One, Detroit, Michigan. 13. Division of Endocrinology, Mayo Clinic, Rochester, Minnesota. 14. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND & AIMS: After the Diabetes Control and Complications Trial (DCCT), the Epidemiology of Diabetes Interventions and Complications (EDIC) study continued to show persistent benefit of prior intensive therapy on neuropathy, retinopathy, and nephropathy in type 1 diabetes mellitus (DM). The relationship between control of glycemia and gastric emptying (GE) is unclear. METHODS: We assessed GE with a (13)C-spirulina breath test and symptoms in 78 participants with type 1 diabetes at year 20 of EDIC. The relationship between delayed GE and glycated hemoglobin (HbA1c), complications of DM, and gastrointestinal symptoms were evaluated. RESULTS: GE was normal (37 participants; 50%), delayed (35 participants; 47%), or rapid (2 participants; 3%). The latest mean HbA1c was 7.7%. In univariate analyses, delayed GE was associated with greater DCCT baseline HbA1c and duration of DM before DCCT (P ≤ .04), greater mean HbA1c over an average of 27 years of follow-up evaluation (during DCCT-EDIC, P = .01), lower R-R variability during deep breathing (P = .03) and severe nephropathy (P = .05), and a greater composite upper gastrointestinal symptom score (P < .05). In multivariate models, retinopathy was the only complication of DM associated with delayed GE. Separately, DCCT baseline HbA1c (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.1-2.3) and duration of DM (OR, 1.2; 95% CI, 1.01-1.3) before DCCT entry and mean HbA1c during DCCT-EDIC (OR, 2.2; 95% CI, 1.04-4.5) were associated independently with delayed GE. CONCLUSIONS: In the DCCT/EDIC study, delayed GE was remarkably common and associated with gastrointestinal symptoms and with measures of early and long-term hyperglycemia. ClinicalTrials.gov numbers NCT00360815 and NCT00360893.
BACKGROUND & AIMS: After the Diabetes Control and Complications Trial (DCCT), the Epidemiology of Diabetes Interventions and Complications (EDIC) study continued to show persistent benefit of prior intensive therapy on neuropathy, retinopathy, and nephropathy in type 1 diabetes mellitus (DM). The relationship between control of glycemia and gastric emptying (GE) is unclear. METHODS: We assessed GE with a (13)C-spirulina breath test and symptoms in 78 participants with type 1 diabetes at year 20 of EDIC. The relationship between delayed GE and glycated hemoglobin (HbA1c), complications of DM, and gastrointestinal symptoms were evaluated. RESULTS: GE was normal (37 participants; 50%), delayed (35 participants; 47%), or rapid (2 participants; 3%). The latest mean HbA1c was 7.7%. In univariate analyses, delayed GE was associated with greater DCCT baseline HbA1c and duration of DM before DCCT (P ≤ .04), greater mean HbA1c over an average of 27 years of follow-up evaluation (during DCCT-EDIC, P = .01), lower R-R variability during deep breathing (P = .03) and severe nephropathy (P = .05), and a greater composite upper gastrointestinal symptom score (P < .05). In multivariate models, retinopathy was the only complication of DM associated with delayed GE. Separately, DCCT baseline HbA1c (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.1-2.3) and duration of DM (OR, 1.2; 95% CI, 1.01-1.3) before DCCT entry and mean HbA1c during DCCT-EDIC (OR, 2.2; 95% CI, 1.04-4.5) were associated independently with delayed GE. CONCLUSIONS: In the DCCT/EDIC study, delayed GE was remarkably common and associated with gastrointestinal symptoms and with measures of early and long-term hyperglycemia. ClinicalTrials.gov numbers NCT00360815 and NCT00360893.
Authors: D A Revicki; A M Rentz; D Dubois; P Kahrilas; V Stanghellini; N J Talley; J Tack Journal: Aliment Pharmacol Ther Date: 2003-07-01 Impact factor: 8.171
Authors: Jessica Chang; Antonietta Russo; Michelle Bound; Christopher K Rayner; Karen L Jones; Michael Horowitz Journal: Diabetes Care Date: 2012-08-13 Impact factor: 19.112
Authors: Subhankar Chakraborty; Magnus Halland; Duane Burton; Anshuman Desai; Bridget Neja; Phillip Low; Wolfgang Singer; Michael Camilleri; Alan R Zinsmeister; Adil E Bharucha Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958